Interstitial lung diseases (ILDs) encompass a broad spectrum of pulmonary disorders characterized by inflammation and fibrosis of the pulmonary interstitium. With over 200 identified types, ILDs present a significant diagnostic and therapeutic challenge for healthcare professionals.
ILDs are primarily driven by inflammation or fibrotic processes, or a combination of both, leading to progressive lung tissue damage. The precise pathophysiology of ILDs remains elusive, but it is believed that recurrent lung injury, followed by abnormal repair mechanisms, plays a crucial role. This process results in irreversible architectural distortion and impaired gas exchange.
ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles, and in advanced stages, signs of pulmonary hypertension or right heart failure. High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, providing detailed views of the lung parenchyma. Lung biopsy, although invasive, may be necessary in certain cases for a definitive diagnosis.
Management of ILDs is complex and often necessitates a multidisciplinary approach. The mainstay of treatment includes corticosteroids and immunosuppressive agents. Novel antifibrotic drugs have shown promise in slowing disease progression in certain ILDs. Lung transplantation may be an option for selected patients with advanced disease. Moreover, palliative care should be integrated into the management plan to address symptoms and enhance quality of life.
Understanding the intricacies of ILDs is essential for healthcare professionals. Despite the challenges, advancements in diagnostic modalities and therapeutic options have improved patient outcomes. Continued research and collaboration are crucial to further elucidate the pathophysiology of ILDs and develop more effective treatments.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation